TherapeuticsMD Gestione

Gestione criteri di controllo 2/4

TherapeuticsMD Il CEO è Brian Bernick, nominato in Sep2022, ha un mandato di meno di un anno. possiede direttamente 0.39% delle azioni della società, per un valore di € 229.63K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.3 anni e 2.6 anni.

Informazioni chiave

Brian Bernick

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	0.4%
Durata media del management	2.3yrs
Durata media del Consiglio di amministrazione	2.6yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Brian Bernick (54 yo)

less than a year

Mandato

US$96,610

Compensazione

Dr. Brian A. Bernick, M.D. serves as Co-Chief Executive Officer at of TherapeuticsMD, Inc since September 2022 and serves as its Chief Medical Officer since September 2022 and served as its Interim Co-Chie...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Thomas Thompson	Executive Chairman	10.4yrs	US$280.00k	0.22% € 125.5k
Hugh O'Dowd	President & Director	1.2yrs	US$5.57m	Nessun dato
Robert Finizio	Co-Founder	no data	US$7.05m	0% € 0
Marlan Walker	General Counsel & Secretay	6.6yrs	US$1.60m	0.055% € 32.0k
Brian Bernick	Co-Founder	less than a year	US$96.61k	0.39% € 229.6k
Mark Glickman	Co-CEO & Chief Business Officer	less than a year	Nessun dato	Nessun dato
Michael Donegan	Interim CFO	9.5yrs	US$572.08k	0.021% € 12.3k
Daniella Silva	Chief Compliance Officer	1.2yrs	Nessun dato	Nessun dato
Benjamin Foulk	Vice President of Human Resources	2.3yrs	Nessun dato	Nessun dato
Mitchell Krassan	Executive VP and Chief Strategy & Performance Officer	11yrs	US$1.04m	Nessun dato
Julia Amadio	Chief Product Officer	10.8yrs	Nessun dato	Nessun dato
Sebastian Mirkin	Chief Medical Officer	8.9yrs	Nessun dato	Nessun dato

2.3yrs

Durata media

54yo

Età media

Gestione esperta: Il team dirigenziale di 29TA è considerato esperto (durata media dell'incarico 2.3 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Thomas Thompson	Executive Chairman	10.4yrs	US$280.00k	0.22% € 125.5k
Hugh O'Dowd	President & Director	less than a year	US$5.57m	Nessun dato
Gail Naughton	Independent Director	2.6yrs	US$192.50k	0.042% € 24.3k
Paul Bisaro	Independent Director	2.6yrs	US$200.00k	0.063% € 36.6k
Angus Russell	Independent Director	7.6yrs	US$207.50k	0.061% € 35.8k
Cooper Collins	Independent Director	10.7yrs	US$212.00k	0.50% € 289.1k
Jules Musing	Independent Director	9.4yrs	US$197.50k	0.043% € 24.9k
Karen Ling	Independent Director	2.5yrs	US$189.50k	0.049% € 28.4k
Justin Roberts	Director	less than a year	Nessun dato	Nessun dato

2.6yrs

Durata media

63.5yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di 29TA non è considerato esperto (durata media del mandato 2.6 anni), il che suggerisce un nuovo consiglio.

TherapeuticsMD Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

TherapeuticsMD, Inc., Annual General Meeting, Dec 05, 2024

TherapeuticsMD, Inc. Announces Executive Changes

TherapeuticsMD, Inc., Annual General Meeting, Jun 26, 2023

TherapeuticsMd, Inc. Announces Executive Changes

Therapeuticsmd, Inc. Appoints Tommy Thompson as Executive Chairman of the Board

TherapeuticsMD, Inc. Appoints Justin Roberts as A Director

Recent updates

TherapeuticsMD, Inc., Annual General Meeting, Dec 05, 2024

TherapeuticsMD, Inc. Announces Executive Changes

TherapeuticsMD, Inc., Annual General Meeting, Jun 26, 2023

TherapeuticsMd, Inc. Announces Executive Changes

Mayne Pharma (USA), Inc. completed the acquisition of Certain Assets of TherapeuticsMD, Inc.

Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

Therapeuticsmd, Inc. Appoints Tommy Thompson as Executive Chairman of the Board

TherapeuticsMD, Inc. Appoints Justin Roberts as A Director

TherapeuticsMD, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Essex Woodlands Management, Inc. cancelled the acquisition of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

TherapeuticsMD, Inc.(NasdaqGS:TXMD) dropped from NASDAQ Biotechnology Index

TherapeuticsMD’s Common Stock No Longer Be Listed on Any Public Market Upon Completion of Transaction with EW Healthcare Partners

Essex Woodlands Management, Inc. entered into a definitive merger agreement to acquire TherapeuticsMD, Inc. (NasdaqGS:TXMD) for $93 million.

Therapeuticsmd, Inc. Receives U.S. Food and Drug Administration (Fda) Approval for Supplemental New Drug Application (Snda) for Annovera®

First quarter 2022 earnings released: US$5.69 loss per share (vs US$5.67 loss in 1Q 2021)

TherapeuticsMD, Inc. to Report Q1, 2022 Results on May 16, 2022

Forecast breakeven date pushed back to 2024

GoodRx Holdings, Inc. (NasdaqGS:GDRX) completed the acquisition of Vitacare Prescription Services, Inc from from TherapeuticsMD, Inc. (NasdaqGS:TXMD) for approximately $160 million.

Forecast breakeven date pushed back to 2024

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

TherapeuticsMD, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Robert G. Finizio Notifies TherapeuticsMD, Inc. of His Decision to Resign from the Board of Directors of the Company and as Vice Chair

Independent Director recently bought €510k worth of stock

Third quarter 2021 earnings released: US$0.11 loss per share (vs US$0.12 loss in 3Q 2020)

Forecast to breakeven in 2023

Executive Vice President of Operations Edward Borkowski has left the company

TherapeuticsMD Announces Issuance of a J-Code for ANNOVERA® to Be Utilized in the Public Health Sector

Independent Director recently bought €619k worth of stock

No longer forecast to breakeven

Second quarter 2021 earnings released: US$0.11 loss per share (vs US$0.19 loss in 2Q 2020)

TherapeuticsMD, Inc.(NasdaqGS:TXMD) dropped from Russell 3000E Value Index

TherapeuticsMD, Inc. Announces Submission of Low Dose BIJUVA® 0.5 mg/100 mg Supplemental New Drug Application to FDA

First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.21 loss in 1Q 2020)

Full year 2020 earnings released: US$0.67 loss per share (vs US$0.71 loss in FY 2019)

Revenue beats expectations

TherapeuticsMD, Inc. to Report Q4, 2020 Results on Mar 02, 2021

TherapeuticsMD, Inc. has completed a Follow-on Equity Offering in the amount of $110 million.

New 90-day high: €1.31

TherapeuticsMD, Inc. Announces the Launch of Just Say Vagina to Encourage Women to Speak Clearly and Directly About Their Reproductive Health

New 90-day low: €0.94

New 90-day low: €1.03

Revenue beats expectations

Third quarter 2020 earnings released: US$0.12 loss per share

TherapeuticsMD, Inc. has completed a Follow-on Equity Offering in the amount of $30 million.

New 90-day low: €1.06

TherapeuticsMD, Inc. to Report Q3, 2020 Results on Nov 09, 2020

Knight Therapeutics Inc and TherapeuticsMD, Inc. Announce Health Canada Approval of BIJUVA

First half earnings released

TherapeuticsMD, Inc. to Report Q2, 2020 Results on Aug 06, 2020

New 90-day high - €1.92

TherapeuticsMD, Inc.(NasdaqGS:TXMD) dropped from S&P Pharmaceuticals Select Industry Index

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media